Generic Name and Formulations:
Dexamethasone 0.1%; oph susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for MAXIDEX:
Adults and Children:
Instill 1–2 drops in the affected eye(s). Severe: may administer hourly, then taper as condition improves. Mild: may administer up to 4–6 times daily.
Acute, untreated bacterial, fungal, mycobacterial, epithelial herpes simplex, or viral (except herpes zoster) infections of the eye.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections and intraocular pressure if used for ≥10 days. Avoid abrupt cessation. Pregnancy. Nursing mothers.
Local irritation, ocular discomfort, increased intraocular pressure, cataracts, corneal perforations, optic nerve damage; may mask or exacerbate infections.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds